key: cord-0882427-cyjua4bf
authors: Swaim, Caleb D.; Dwivedi, Varun; Perng, Yi-Chieh; Zhao, Xu; Canadeo, Larissa A.; Harastani, Houda H.; Darling, Tamarand L.; Boon, Adrianus C.M.; Lenschow, Deborah J.; Kulkarni, Viraj; Huibregtse, Jon M.
title: 6-Thioguanine Blocks SARS-CoV-2 Replication by Inhibition of PLpro
date: 2021-10-02
journal: iScience
DOI: 10.1016/j.isci.2021.103213
sha: 066a241a3ed12272a611234021ae3721ae587fec
doc_id: 882427
cord_uid: cyjua4bf

The emergence of SARS-CoV-2 has led to a global health crisis that, in addition to vaccines and immunomodulatory therapies, calls for the identification of antiviral therapeutics. The papain-like protease (PLpro) activity of nsp3 is an attractive drug target as it is essential for viral polyprotein cleavage and for deconjugation of ISG15, an antiviral ubiquitin-like protein. We show here that 6-Thioguanine (6-TG), an orally available and widely available generic drug, inhibits SARS-CoV-2 replication in Vero-E6 cells with an EC50 of approximately 2 μM. 6-TG also inhibited PLpro-catalyzed polyprotein cleavage and de-ISGylation in cells and inhibited proteolytic activity of the purified PLpro domain in vitro. We therefore propose that 6-TG is a direct-acting antiviral that could potentially be repurposed and incorporated into the set of treatment and prevention options for COVID-19.

Coronavirus Disease-2019 (COVID-19) is caused by SARS-CoV-2, a betacoronavirus highly similar to SARS-CoV-1 (now SARS-CoV-1) (Coronaviridae Study Group of the International Committee on Taxonomy of Viruses, 2020); (Gralinski and Menachery, 2020 ). An urgent need exists for additional treatment strategies, and repurposed FDA-approved drugs with existing supply chains and well characterized pharmacologic properties represent a rapid and efficient approach toward COVID-19 therapeutics (Guy et al., 2020) .

Enzymatic activities encoded by SARS-CoV-2 are attractive drug targets, including PLpro, an essential cysteine protease within the large multi-domain nsp3 protein (Harcourt et al., 2004) . PLpro cleaves the pp1a polyprotein at three sites and is required to generate the mature nsp1, 2, 3 and 4 proteins. These proteins modulate host cell translation (nsp1) and contribute to formation of viral replication/transcription complexes (nsp2, 3, 4) (V'kovski et al., 2021) . The PLpro recognition consensus site within pp1a (LXGG) is also found at the Cterminus of ubiquitin and ISG15, an antiviral ubiquitin-like modifier, although PLpro of MERS-CoV, SARS-CoV-1 and SARS-CoV-2 PLpro preferentially catalyzes de-ISGylation over ubiquitylation (Daczkowski et al., 2017; Freitas et al., 2020) . The fact that these viruses encode de-ISGylase activity suggests they are sensitive to the antiviral effects of ISGylation.

Therapeutic inhibition of PLpro would therefore be predicted to have two antiviral effects:

inhibition of viral replication by blocking polyprotein cleavage and restoration of the antiviral effects of ISGylation. Further, de-ISGylation by PLpro, through generation of free (unconjugated) ISG15, enhances the secretion and extracellular signaling function of ISG15, which in turn promotes pro-inflammatory cytokine production from cells of the immune system (Swaim et al., 2020) . Therefore, a potential third effect of inhibiting PLpro would be a decrease in the pro-inflammatory "cytokine storm" associated with COVID-19 (Tay et al., 2020) . Here, we

show that an inhibitor of SARS-CoV-2 PLpro, 6-thioguanine (6-TG), inhibits virus replication at J o u r n a l P r e -p r o o f low micromolar concentrations. 6-TG is a widely available generic drug that could therefore potentially be repurposed as a betacoronavirus therapeutic in the current and future pandemics.

J o u r n a l P r e -p r o o f

6-Thioguanine ( Figure 1A ) has been used clinically since the 1950s, originally for the treatment of childhood leukemias and subsequently for long-term treatment of inflammatory bowel disease (IBD) and Crohn's disease (Bayoumy et al., 2020) . 6-TG was previously reported to inhibit the SARS-CoV-1 and MERS-CoV PLpro catalytic domain in vitro (Cheng et al., 2015; Chou et al., 2008) , however there was no further follow up of its ability to inhibit de-ISGylation or viral polyprotein cleavage in cells or its ability to inhibit viral replication. 6-TG was therefore tested for its ability to inhibit SARS-CoV-2 replication in Vero-E6 African Green Monkey kidney cells. As shown in Figure 1B , 6-TG inhibited viral replication with a half-maximal effective concentration (EC50) of 2.13 µM. Remdesivir, a SARS-CoV-2 therapeutic and an inhibitor of the viral RNA-dependent RNA polymerase (Yin et al., 2020) , inhibited replication with a very similar EC50, 2.16 μM. GRL0617, a previously reported inhibitor of SARS-CoV-2 PLpro inhibited replication with an EC50 approximately 15-fold higher than 6-TG (35.43 μM), consistent with previously reported results (Freitas et al., 2020) . Azathioprine, a thiopurine related to 6-TG that is also used clinically for IBD (Bayoumy et al., 2020) , was approximately 10fold less effective at inhibiting viral replication than 6-TG (EC50 19.16 μM). The cytotoxicity of these compounds was determined, and the CC50 (50% cytotoxic concentration) ranged from approximately 35 µM for 6-TG to 60 µM for Remdesivir (Supplemental Figure S1 ). cysteine within the PLpro domain of nsp3 altered to an alanine (TAP-nsp123 C-A ). The fusion proteins were detected by immunoblotting of cell lysates with anti-TAP antibody, and TAP-nsp1 was expressed separately as a size marker for the processed fusion protein. Expression of TAP-nsp123 WT resulted primarily in a product the size of TAP-nsp1 (42 kD), as expected if the fusion protein was fully processed, while expression of TAP-nsp123 C-A resulted in the expected full-length protein (336 kD) along with several breakdown products of the full-length protein.

Increasing concentrations of 6-TG inhibited PLpro-mediated processing of the TAP-nsp123 WT polyprotein, with loss of the TAP-nsp1 product and accumulation of the full-length fusion protein, with the same pattern of breakdown products seen with the TAP-nsp123 C-A protein ( Figure 2A ).

Half-maximal inhibition of polyprotein cleavage occurred at approximately 0.5 µM 6-TG (quantitation shown in Supplemental Figure S2A ). In a related experiment ( Figure 2B ), the isolated PLpro domain (residues 746-1061 of nsp3) was co-expressed in trans with a TAPtagged nsp2-nsp3 fragment (residues 727-918 of pp1a), spanning the nsp2-3 PLpro cleavage site. PLpro efficiently processed the TAP-nsp2-3 protein, dependent on the active-site cysteine, and this was again inhibited with increasing amounts of 6-TG, with half-maximal inhibition at approximately 1.0 µM 6-TG (quantitation shown in Supplemental Figure S2B ).

In addition to polyprotein cleavage activity, SARS-CoV-2 PLpro deconjugates ISG15 from proteins that have been modified by this antiviral ubiquitin-like protein (Klemm et al., 2020; Shin et al., 2020; Swaim et al., 2020) . The E1, E2, and E3 enzymes for conjugation of human ISG15 are Uba7, Ube2L6, and Herc5, respectively, and expression of these enzymes with ISG15 results in robust protein ISGylation in cells (Dastur et al., 2006) . Figure 3A shows that co-expression of PLpro (residues 746-1061 of nsp3) with ISG15 and the ISG15 conjugation enzymes in HEK293T cells resulted in nearly complete loss of ISG15 conjugates, while expression of the active-site C-to-A variant of PLpro (PLpro C-A ) did not. Addition of 6-TG resulted in a dose-dependent inhibition of PLpro de-ISGylation activity, with half-maximal inhibition at approximately 0.1 µM (quantitation shown in Supplemental Figure S2C ). To J o u r n a l P r e -p r o o f 7 demonstrate that 6-TG acts directly on PLpro, an in vitro cleavage assay was established based on an ISG15 fusion protein. Like most ubiquitin-like proteins, ISG15 is synthesized in cells as a precursor protein with a C-terminal extension that must be proteolytically removed prior to conjugation. We expressed and purified the precursor form of ISG15 with an additional Cterminal HA tag (Pro-ISG15-HA), and this was used as a substrate for the purified PLpro domain (nsp3 residues 746-1061). As shown in Figure 3B , purified PLpro proteolytically removed the HA-tagged C-terminal extension, and increasing amounts of 6-TG inhibited the reaction, dependent on the input amount of PLpro enzyme (quantitation shown in Supplemental Figure S2D ). These results indicate that 6-TG directly inhibits SARS-CoV-2 PLpro.

The results shown here indicate that 6-TG is a direct-acting SARS-CoV-2 antiviral that functions by inhibiting the PLpro activity of the nsp3 protein. 6-TG inhibited both pp1a polyprotein processing in cells and the ISG15 deconjugation activity of PLpro in cells and in vitro. Pp1a polyprotein cleavage is essential for generation of the nsp1-4 viral proteins, and therefore essential for virus replication. Inhibition of ISG15 conjugation is likely to have a less important effect in cell-based replication assays but may have important consequences during an infection in an animal or human host. The fact that MERS-CoV and SARS-CoV-1 PLpro also have de-ISGylase activity suggests these viruses are particularly sensitive to the antiviral effects of ISG15. While the critical targets of ISG15 conjugation in infected cells are not yet known, we speculate that these may include newly translated viral proteins, as suggested earlier (Durfee et al., 2010) , and perhaps the pp1a protein, itself.

6-TG is an orally-delivered generic drug on the World Health Organization list of essential medicines, suggesting that it could be potentially re-purposed as an inexpensive and widely available therapeutic for COVID-19. Clinical trials are essential for determining the effectiveness of 6-TG against COVID-19. Four clinically approved hepatitis C protease inhibitors (Semeprevir, Paritaprevir, Vaniprevir, and Grazoprivir) have also recently been shown to inhibit SARS-CoV-2 PLpro in vitro and virus replication in Vero-E6 cells (Bafna et al., 2021) .

The EC50s for inhibition of viral replication for these drugs ranged from 4.25 to 10.8 μM, while that of 6-TG was determined here to be 2.13 μM. While 6-TG directly inhibited PLpro activity, it should be noted that the mechanism of action of 6-TG as a chemotherapeutic and immunosuppressant is that it is converted into 6-Thioguanine ribonucleotides and deoxynucleotides and incorporated into RNA and DNA. It is therefore possible that incorporation of 6-TG-containing ribonucleotides into SARS-CoV-2 RNA could be a secondary antiviral effect of 6-TG.

Current 6-TG dosing in patients varies significantly, from 0.3 mg/kg/day for long-term treatment of inflammatory diseases, to up to 3 mg/kg/day in acute lymphocytic and myelogenous leukemia treatments (Seinen et al., 2010) . Hepatotoxicity and bone marrow suppression are significant side effects of high dose treatment (2-3 mg/kg/day), however this is typically not seen before two courses of treatment (2 months). 6-TG as an IBD therapeutic involves continuous doses of 0.3 mg/kg/day for more than a year, a dosage that results in fewer cases of liver and myeloid toxicities (Meijer et al., 2016; Mulder et al., 2014) . While it may seem counterintuitive to use a immunosuppressive as an antiviral, evidence to date indicates that IBD patients on thiopurine therapies do not have higher rates of COVID-19 than the general population (Higgins et al., 2020) . Further, as a potential COVID-19 treatment, we anticipate that 6-TG treatment courses would be on the order of 5-10 days, like Remdesivir, and therefore toxicities and immune-suppression associated with prolonged or high dose 6-TG treatment are unlikely to be relevant. Also like Remdesivir, we anticipate that 6-TG would be most effective if administered early in the course of a SARS-CoV-2 infection, during the peak viral replication phase. We note that unlike 6-TG, Remdesivir must be delivered intravenously. We propose that the results presented here warrant the initiation of human clinical trials of 6-TG as a SARS-CoV-2 therapeutic. As PLpro is a conserved and essential enzymatic activity of the beta coronaviruses, 6-TG may prove useful in the current and future coronavirus pandemics and as a complement to other antivirals in use and in development. 

The structure of 6-Thioguanine (6-TG). B. Vero-E6 cells were treated with 6-TG, Remdesivir, GRL0617, and Azathioprine to assess their ability to restrict SARS-CoV-2 replication (MOI: 0.01). Drug concentrations for 6-TG, GRL0617 and Azathioprine ranged from 0.1 pM to 100 µM at 10-fold increments; concentrations for Remdesivir ranged from 5 nM to 100 µM at 3-fold increments.

Percent inhibition of viral replication was calculated by comparing plaques in drug-treated samples to those in DMSO treated samples and shown as mean ± SED for either four replicates (6-TG, GRL0617 and Azathioprine) or two replicates (Remdesivir). The calculated EC50 for the compounds are shown in each panel with 95% confidence limits. J o u r n a l P r e -p r o o f Plasmids pcDNA3.1-TAP-PLpro WT and pcDNA3.1-TAP-PLpro CA were described in (Swaim et al., 2020) . pcDNA3.1-TAP-nsp123 was generated from a partial orf1ab clone (S2-A2_p57 plasmids) encoding residues 1-1504; nsp1, nsp2, and part of nsp3; (gift from Hongbing Jiang and David Wang, Washington University School of Medicine ) with the remainder of the nsp3 ORF (residues 1505 -2767 of pp1a, derived from Addgene cat# 141257). The pcDNA3.1-TAP-nsp123 active site variant (C to A substitution, residue 1675 of polyprotein 1a, corresponding to residue 856 of mature nsp3) was generated from this clone by overlapping PCR. Plasmids expressing FLAG-ISG15, and the ISG15 E1, E2, and E3 enzymes (Uba7, Ube2L6, and Herc5) have been described previously (Swaim et al., 2017) . Pro-ISG15-HA was generated by appending the natural C-terminal ISG15 extension and an HA-tag (GTEPGGRSYPYDVPDYA) to the C-terminus of FLAG-ISG15. The TAP-nsp2-3 was generated by amplifying the region encoding the last 92 amino acids of nsp2 and the first 100 amino acids of nsp3 (residues 727-918 of pp1a) from TAP-nsp123 and cloning it into pcDNA-NTAP using the BamH1 and Not1 restriction sites.

Transfections and drug treatments HEK293T cells were plated in a 6 well plate at a density of 3x10 4 cells/mL. The next day cells were transfected using X-tremeGENE HP DNA transfection reagent (Roche). Plasmids were transfected at the following amounts: 0.35 µg FLAG-ISG15, 0.25 µg Uba7, 0.25 µg Ube2L6, 0.35 µg HA-Herc5, 1 µg TAP-nsp123 (WT or CA), 0.2 µg TAP-PLpro (WT or CA) Cells were treated with 6-TG at the indicated concentrations immediately following transfection (100 mM 6-TG stock in DMSO and diluted in PBS).

Sars-CoV-2 PLpro was purified as a GST fusion protein in BL12 E. coli. Overnight starter cultures were grown at 37ºC for 16 hours. Cultures were diluted 1:10 and cultured with shaking for 2 hours at 37ºC. Expression of protein was induced with 100 µM Isopropyl β-D-1thiogalactopyranoside (IPTG) for 24 hours at 16ºC. Cells were collected by centrifugation, resuspended in 10 mL TBS with 0.00025% Tween 20, 0.01 mM DTT and 5% glycerol (Binding Buffer), and sonicated for 1 minute. Lysates were spun at 15,000 x g for 10 minutes and supernatants were incubated with 100 µL per liter of culture Glutathione Sepharose (GE Healthcare) for 4 hours with rotation at 4ºC. Beads were collected and washed three times with Binding Buffer supplemented with 0.1mM EDTA and subjected to site-specific cleavage with PreScission Protease (GE Healthcare) to remove the GST tag. Beads were removed and the protein concentration in the supernatant was quantified by SDS-PAGE using a Licor Odyssey Imager.

Pro-ISG15-HA was purified as a GST fusion from BL21 E. coli. Overnight starter cultures were grown at 37ºC. Cultures were diluted 1:10 with shaking for 2 hrs at 37ºC. Expression of protein was induced with 100 µM Isopropyl β-D-1-thiogalactopyranoside (IPTG) for 3 hours at 30ºC. Cells were collected by centrifugation and resuspended in PBS with 1% Triton X and sonicated for 30 seconds. Lysates were spun at 15,000 x g for 10 minutes and supernatants were incubated with 100 µL per liter of culture Glutathione Sepharose (GE Healthcare) for 4 hours with rotation at 4ºC. Beads were collected and washed three times with Binding Buffer supplemented with 0.1mM EDTA and subjected to site-specific cleavage with PreScission Protease (GE Healthcare) to remove the GST tag. Beads were removed and the protein concentration in the supernatant was quantified by SDS-PAGE using a Licor Odyssey Imager.

Pro-ISG15-HA cleavage assay J o u r n a l P r e -p r o o f

The indicated concentrations of PLpro were incubated with increasing concentrations of 6-TG for 1 min at a 40 µL volume. 100 ng (166 nM) of Pro-ISG15-HA was added to the PLpro-6-TG reactions for 30 min. The reactions were stopped with the addition of 10µL of loading buffer (25mM Tris pH6.8 40% glycerol, 8%SDS and 4mM DTT) and analyzed by HA-immunoblot; loss of the HA tag reflects proteolytic cleavage by PLpro.

Samples assessing ISGylation were lysed in 1% NP40 lysis buffer (100 mM Tris pH 7.5, 100 mM NaCl ,1% NP40) supplemented with 10 mM NEM, 170 µg/mL PMSF, 2 µg/mL leupeptin, 2 µg/mL aprotinin and 10 mM DTT for 10 minutes on ice followed by a 10 minute spin at 20,000 x g. Samples were run on BOLT 4-12% Bis-Tris gels (Thermo) and blotted with anti-M2 FLAG antibody (Sigma) and anti-actin (Invitrogen AC-15). Samples assessing the effect of 6-TG on TAP-nsp123 cleavage were lysed in RIPA buffer (50 mM Tris pH 8, 150 mM NaCl, 0.5% NP40, 0.1% SDS, 0.5% Sodium deoxycholate w/v) supplemented with 10 mM NEM, 170 µg/mL PMSF, 2 µg/mL leupeptin, 2 µg/mL aprotinin, 10 mM DTT, and 2 units/mL Universal Nuclease (Pierce) and incubated for 10 minutes on ice followed by a 10 minute spin at 20,000 x g. Samples were run on 3-8% Tris-Acetate gels (Thermo) and blotted for TAP using anti-protein A antibody (Sigma) and anti-actin (Invitrogen AC-15).

Vero-E6 cells (2 x 10 4 cells/well) were seeded in 96-well culture plates in DMEM +10% FBS+P/S/G and incubated at 37°C, 5% CO2. After 24 h, Vero-E6 cells were infected with SARS-CoV-2 (MOI 0.01; 50 μl) for 1 h at 37°C; 5% CO2. After 1 h of viral adsorption, virus inoculum was removed and post-infection media (DMEM + 2% FBS + P/S/G) containing ten-fold serially diluted 6-TG, GLR0617, and Azathioprine (100 μM to 0.1 pM) with 1% Avicel was added. Remdesivir was diluted 3-fold (100 μM-0.01 μM) and served as a positive control. Cells J o u r n a l P r e -p r o o f infected with SARS-CoV-2 only, cells alone (mock infected cells), and DMSO, were included as controls. At 24 h post-infection, the overlay media was removed and plates were fixed overnight in 10% neutral buffered formalin (Sigma-Aldrich), followed by 3 washes with PBS. Cells were stained with SARS-CoV nucleocapsid (N) protein cross-reactive monoclonal antibody (mAb, 1C7C7, Cat# ZMS1075, Sigma-Aldrich, Saint Louis, MO) diluted in 1% Bovine Serum Albumin (BSA,1 μg/ml) for 1 h at 37°C and washed with PBS. 150 µL of biotinylated secondary antibody was added (Vector Laboratories PK-4000) for 30 min at 37ºC with 5% CO2. Post secondary antibody incubation the ABC reagent was added for 30 min at room temperature (Vector Laboratories PK-4000). Plates were washed 3 times with PBS and developed using DAB staining (Vector Laboratories SK-4100) per manufacturer's instructions. The plates were scanned using a CTL ImmunoSpot plate reader, and formed plaques were counted by an automated counting software (Cellular Technology Limited, Cleveland, OH, USA). Plaque forming units were calculated relative to DMSO treated controls.

CellTiter-Glo 2.0 (Promega) was used to determine the cytotoxicity of Remdesivir, 6-TG, GLR0617, and Azathioprine. Vero-E6 cells were seeded in a 96 well white clear bottom plate at 2.5x10 5 cells per well in 100 µL of media for 16 hours. Compounds including a DMSO control were added at the indicated concentrations for 48 hours in triplicate. After 48 hours the plate was brought to room temperature and 100µL of CellTiter-Glo 2.0 was added to each well. The plate was placed on an orbital shaker for 2 minutes and then incubated in the dark for 10 minutes. The plate was read on a spectromax M3 plate reader luminometer with an integration time of .5 seconds per well. Luminescence of compound treated samples was compared to nocell background and to DMSO treated cells to determine percent survival, and plotted using Graphpad Prism 9. Non linear fit vs. normalized response with variable slope was used to calculate CC50 values for each compound.

Quantification and statistical analysis.

Graphpad Prism 9 software was used to plot virus replication and densitometry data.

Bars represent three or more biological replicates. Error bars represent the standard error of the mean (SEM). Ordinary one-way ANOVA was performed on each data set. A non-linear regression curve fit analysis over the dilution curve was performed to calculate EC50 and CC50 of the compounds. Cell viability, dose response curve, and EC50 with 95% confidence intervals are indicated on the graph (Supplemental Figure S2 ).

J o u r n a l P r e -p r o o f

Hepatitis C virus drugs that inhibit SARS-CoV-2 papain-like protease synergize with remdesivir to suppress viral replication in cell culture

The continuous rediscovery and the benefit-risk ratio of thioguanine, a comprehensive review

Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus

Thiopurine analogues inhibit papain-like protease of severe acute respiratory syndrome coronavirus

The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

Structurally Guided Removal of DeISGylase Biochemical Activity from Papain-Like Protease Originating from Middle East Respiratory Syndrome Coronavirus

Herc5, an interferoninduced HECT E3 enzyme, is required for conjugation of ISG15 in human cells

The ISG15 conjugation system broadly targets newly synthesized proteins: implications for the antiviral function of ISG15

Characterization and Noncovalent Inhibition of the Deubiquitinase and deISGylase Activity of SARS-CoV-2 Papain-Like Protease

Return of the Coronavirus: 2019-nCoV

Rapid repurposing of drugs for COVID-19

Identification of severe acute respiratory syndrome coronavirus replicase products and characterization of papain-like protease activity

The Risk of SARS-CoV-2 in Immunosuppressed IBD Patients

Efficacy of thioguanine treatment in inflammatory bowel disease: A systematic review

Drug Rediscovery to Prevent O-Label Prescription Reduces Health Care Costs: the Case of Tioguanine in e Netherlands

Dosing 6-thioguanine in inflammatory bowel disease: expert-based guidelines for daily practice

Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity

Modulation of Extracellular ISG15 Signaling by Pathogens and Viral Effector Proteins

The trinity of COVID-19: immunity, inflammation and intervention

Coronavirus biology and replication: implications for SARS-CoV-2

We thank Robert Krug and Sylvie Beaudenon-Huibregtse for critical reading of the manuscript and Bill Matsui for helpful discussions.